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Abstract
Objective: To assess the test qualities of four screening methods to detect cervical
intra-epithelial neoplasia in an urban African setting. Method: Six hundred fifty-
three women, attending a family planning clinic in Nairobi (Kenya), underwent four
concurrent screening methods: pap smear, visual inspection with acetic acid (VIA),
PCR for high risk human papillomavirus (HR HPV) and cervicography. The presence of
cervical intra-epithelial neoplasia (CIN) was verified by colposcopy or biopsy. Result:
Sensitivity (for CIN2 or higher) and specificity (to exclude any CIN or cancer)
were 83.3% (95% CI [73.6, 93.0]) and 94.6% (95% CI [92.6, 96.5]), respectively,
for pap smear; 73.3% (95% CI [61.8, 84.9]) and 80.0% (95% CI [76.6, 83.4]) for
VIA; 94.4% (95% CI [84.6, 98.8]) and 73.9% (95% CI [69.7, 78.2]) for HR HPV; and
72.3% (95% CI [59.1, 85.6]) and 93.2% (95% CI [90.8, 95.7]) for cervicography.
Conclusion: The pap smear had the highest specificity (94.6%) and HPV testing
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the highest sensitivity (94.4%). The visual methods, VIA and cervicography, were
similar and showed an accuracy in between the former two tests.
D 2005 International Federation of Gynecology and Obstetrics. Published by
Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Screening for cervical lesions has proven successful
in the industrialized world, with incidences of
cervical cancer reduced by 80% in countries with
organized screening and treatment programs [1].
The success of these programs can largely be
attributed to the use of the Papanicolaou (pap)
smear [2]. In the developing world, however, the
incidence of cervical cancer remains high, partic-
ularly in sub-Saharan Africa, where cervical cancer
is the most common cancer in women [3]. The lack
of organized cervical cancer control programs is the
main reason for this. Effective cytological screening
programs are difficult to implement in low resource
settings because of high cost, training requirements
for laboratory technicians, and competing health
priorities. Alternative screening methods are there-
fore being assessed. This paper reports on the test
qualities of pap smear, visual inspection with acetic
acid (VIA), cervicography, and DNA-PCR testing for
human papillomavirus (HPV).
2. Materials and methods
Between January 1998 and July 2000, a cross-
sectional study was carried out in non-pregnant
women aged 25—55 attending a family planning
clinic in Nairobi, Kenya. The study was approved by
the National Ethical Review Committee of Kenyatta
National Hospital, Nairobi. The staff consisted of a
study nurse, who received a 4-day training in the
technique of VIA with a pictorial atlas for visual
inspection of the cervix [4] and projected images
of cervices, followed by hands-on training, and two
medical doctors trained in colposcopy.
Each working day, the first eight consecutive
clients presenting at the family planning clinic
were invited to participate in the study. A signed
informed consent was obtained from all partic-
ipants. The study nurse was blinded to the clinical
background (referred patients or women attending
for family planning). At the first visit (V1),
exfoliative cervical cells were obtained using a
Cervex Brush (Rovers Medical Devices, Oss, The
Netherlands). One smear was made on a glass slide
for staining according to the Papanicoloau
method. The brush was then submerged and
stirred in 10 ml phosphate buffered saline (PBS)
and frozen at 20 8C. A VIA (VIA1) examination
was then performed (inspecting the transforma-
tion zone) after application of commercially
available vinegar (acetic acid 3—5%) for 2 min
and illumination with a halogen torch. VIA findings
were recorded by the study nurse in a clinical
records form (CRF). Two photographic slides were
taken with a specially designed 35 mm reflex
camera (cervicography) (National Testing Labora-
tories, Fenton, USA). Serum samples were
obtained for HIV testing after pretest counseling.
Blood samples were tested for HIV-1 and HIV-2
using ELISA Detect HIV1/2 (Immunosystems, Mon-
treal, Quebec) and Recombigen HIV1/2 (Trinity
Biotech, Galway, Ireland). All the women were
invited to come for a follow-up visit after 3 weeks
(V2). At this visit, VIA (VIA2) was performed on all
women by the study nurse and colposcopy by the
doctor. After these examinations, the findings
were registered in the CRF and the result of the
pap smear disclosed to the examinators and
communicated to the woman. If the pap smear,
VIA2, or colposcopy was positive, a biopsy and/or
endocervical curettage was obtained.
Pap smears and cervical biopsies were processed
and analyzed at the Department of Human Pathol-
ogy, University of Nairobi, Kenya. Cytology was
reported according to the Bethesda 1991 classifica-
tion. All positive smears and 60% of the negatives,
randomly chosen, were sent to the Department of
Pathology, Antwerp University, Belgium for quality
review. A Cohen’s Kappa for agreement of 0.623 was
found between the two institutions. The original
Nairobi results before quality review were used in
this analysis. All histology specimens were also
reviewed and the Antwerp results were used for
final data analysis. HPV samples were shipped to the
Laboratory of Virology, Ghent University, Belgium
for HPV DNA extraction, detection and genotyping,
as described earlier [5]. Cervicography slides were
assessed at the department of gynecology, Free
University of Brussels, Belgium, by a senior staff
colposcopist and accredited cervicography evalua-
tor (PDS).
All examiners interpreting pap smears, HPV DNA
PCR, or cervicographies were blinded to the clinical
background and to other screening test results.
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A pap smear was considered positive in case of
LSIL or more severe lesions. VIA was considered
positive in case of well defined, distinct acetowhite
lesions on the cervix, close to the os. Colposcopy
was considered positive for a colposcopic impres-
sion of LSIL or more. Any abnormal result on biopsy
was taken as the final positive diagnosis, hereafter
called the breference testQ. If biopsy was negative,
or in case there was no indication for biopsy (all
screening tests and colposcopy were negative), the
reference test was considered negative. Lesions of
CIN2 or worse on the reference test are considered
as diseased and reported as dcasesT. The presence
of any HPV DNA resulted in a positive HPV test, but
we also assessed the presence of DNA from high-risk
HPV types (HPV HR).
Cervicographies were reported using the classi-
fication criteria proposed by Schneider et al. [6].
All grades equal to or higher than a low grade
lesion were considered as a positive test result.
Data were entered in Epi-info (CDC, USA; WHO,
Geneva) and analyzed in SPSS 10.0.5 for windows
(SPSS, Chicago, IL, USA). Comparisons of catego-
rical variables were made using Pearson’s X2 and
Fisher’s exact tests. Means of continuous variables
were compared using the Independent Samples t-
test. Exact 95% confidence intervals for diagnostic
sensitivity (positive test results compared to the
reference test) and specificity (negative test
results compared to the reference test) were
reported where appropriate.
3. Results
3.1. Characteristics of the study population
Of the 816 women presenting at Visit 1, 653
attended the clinic for visit 2 and were included in
the study. The majority (548, 83.9%) were women
who attended the clinic for family planning
services (screening group). Another 105 women
were referred because of an abnormal pap smear
or for clinical reasons (referred group).
The distribution of demographic characteristics
and risk factors for both groups is shown in Table 1.
No significant differences in CIN detection or
demographical variables were found between the
group presenting for V1 and the group attending for
V2 (data not shown).
3.2. Detection of CIN and carcinoma
A total of 255 biopsies were taken, on which 114
lesions were found. Table 2 shows the number of
CIN lesions and invasive squamous cell carcinoma
in the screening and the referred group. Lesions
were more prevalent in the referred group. For
assessment of the test qualities of the different
screening methods, results from both groups are
combined.
3.3. Pap smear
Of the 653 pap smears, 629 were bsatisfactory for
evaluationQ (96.3%) (Table 3), and 16.7% of the
adequate smears showed LSIL or worse. All 6 cases
of invasive squamous cell cancer were detected. Of
the 54 CIN2/3 cases, 44 (81.5%) were diagnosed on
pap smear as LSIL or worse. Similarly, 27 (50.0%) of
the 54 CIN1 cases were detected. Of the positive
pap smears, 26.7% yielded a normal reference test.
3.4. VIA
One hundred seventy-seven VIA examinations were
positive at visit 1 (27.1%) (Table 3). Four of the
invasive squamous cell cancers were diagnosed
(66.7%), 40 (74.1%) of the CIN2/3 cases, and 25
(46.3%) of the CIN1 cases. One hundred and eight
(61.0%) positive VIA tests were normal on the
reference test.
3.5. HPV DNA PCR
Five hundred sixteen HPV DNA PCR test results
were available (Table 3). For hundred twenty
Table 2 Prevalence of CIN and cancer in the screen-







CIN1 34 (6.2%) 20 (19.0%) 54 (8.3%)
CIN2/3 30 (5.5%) 24 (22.9%) 54 (8.3%)
Inv. squamous
cell carcinoma
1 (0.2%) 5 (4.8%) 6 (0.9%)
Table 1 Comparison of risk factors for cervical (pre-)






Mean age 35.8 34.1 0.02
Mean parity 2.9 2.7 0.4
Mean age first sex 19.4 18.6 0.01
Monogamous marriage 76.2% 64.4% 0.02
Single 12.7% 24.4% 0.004
More than 1 regular
partner
0.8% 4.5% 0.006
Lifetime partnersz4 21.2% 28.8% 0.09
HIV prevalence 11.3% 29.8% b0.001
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women, no HPV sample was taken, because of
unavailability at the clinic of the PBS sampling
medium, which had to be prepared freshly on
a regular basis. Four HPV tests had a border-
line (equivocal) result and 13 were indetermi-
nate. These cases were excluded from the
analysis.
Two hundred fifty-six (49.6%) women had a
positive HPV test, 193 (37.4%) were infected with
a HR HPV type. All invasive cancers were positive
for a HR HPV type. Forty-six (95.8%) of the CIN2/
3 cases had a positive HPV test, 45 (93.8%) had
an HR HPV type. Thirty-six (75.0%) of the women
with CIN1 were HPV positive, 34 (70.9%) were
infected with an HR HPV type. One hundred
sixty-eight (65.6%) women with HPV had a normal
reference test, compared to 108 (56.0%) of the
women with HR HPV.
3.6. Cervicography
A total of 523 cervicographies were taken in this
group (Table 3), and fifteen images were tech-
nically defective. One hundred and thirty cervi-
cographs are missing because of breakdown of
the camera at one time. Seventy-eight of the
cervicographies (15.4%) indicated a cervical
lesion. All the invasive cancer cases tested
positive, 29 (69.0%) of the CIN2/3 and 16
(33.3%) CIN1. Twenty-eight (35.9%) of the women
with a positive cervicography had a normal
reference test.
3.7. Comparison of the four screening tests
Table 4 shows estimates for the sensitivity and
specificity of the four screening tests. For cases of
Table 3 Results of screening tests compared to biopsy results
N Reference test biopsy
Normal CIN 1 CIN 2 CIN 3 Cancer
Pap smear
Unsatisfactory 24 23 1 0 0 0
Normal 481 451 23 2 5 0
ASCUS 43 37 3 2 1 0
LSIL 37 18 12 5 2 0
HSIL 50 7 14 5 23 1
Cancer 18 3 1 2 7 5
Total 629 516 53 16 38 6
VIA
Negative 476 431 29 6 8 2
Positive 177 108 25 10 30 4
Total 653 539 54 16 38 6
HPV
Defectivea 17 17 0 0 0 0
Negative 260 246 12 0 2 0
Positive 256 168 36 16 30 6
HPV excl. LRb 31 30 1 0 0 0
HPV HRc 193 108 34 16 29 6
HPV Xd 32 30 1 0 1 0
Total 516 414 48 16 32 6
Cervicography
Tech defective 15 11 1 1 2 0
Neg 390 353 25 5 7 0
Atypical 23 18 5 0 0 0
Atyp/colpe 17 14 2 0 1 0
Lgrade 21 11 5 3 1 1
Hgrade 51 17 10 5 16 3
Cancer 6 0 1 1 3 1
Total 508 413 48 14 28 5
a Borderline or indeterminate samples.
b Samples with exclusively LR HPV types.
c Samples containing HR HPV types.
d Samples with an unknown HPV type.
e Atypical cervicographies, colposcopy is warranted.
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CIN2 or worse, the pap smear showed a sensitivity
of 83.3% and a specificity of 90.3%. The highest
sensitivity (96.3%) was found with HPV testing (any
type). However, the rate of false positives was
considerably higher, yielding a specificity of 55.8%.
Considering only HPV HR results as positive test
results did not change the sensitivity significantly
(94.4%), but did increase the specificity (69.3%).
VIA scored a sensitivity and specificity of 73.3% and
77.6%, respectively, and cervicography 72.3% and
90.5%, respectively.
4. Discussion
This study was designed to compare the test
qualities of alternative screening methods for the
detection of CIN and invasive cervical cancer, which
could be used in poor resource regions. This was a
clinic-based population with a small proportion of
referred women who contributed to the high
number of (pre-)cancerous lesions.
Biopsy results were missing for 20 women with
positive VIA2 but negative colposcopy, and 6
women with positive VIA2 and colposcopy sugges-
tive of a low grade lesion. All 26 women had a
negative pap smear. We kept these cases in the
dataset, considering them negative on the refer-
ence test. Deleting these cases from the analysis
would introduce a considerable bias towards fewer
false positive VIA results.
The pap smear performed well with a sensitiv-
ity of 83.3% and a specificity of 90.3% for CIN2+.
This test was performed at a referral and training
center, which cautions that these results cannot
be generalized for other cytology laboratories in
the region. Indeed, a meta-analysis on pap test
accuracy reported ranges for sensitivity and
specificity of 11—99% and 14—97%, respectively
[7]. This author concluded that pap test accuracy
was not associated with reported study character-
istics or dimensions of quality. In a similar study in
Zimbabwe, pap smear performed with a sensitiv-
ity and specificity of 44.3% and 90.6%, respec-
tively [8].
Most studies on HPV testing for cervical cancer
screening use the Digene HPV Hybrid Capture II
test, which detects 13 HR HPV types and 5 LR HPV
types. Compared to our method, the Digene test
had a slightly lower sensitivity and higher specific-
ity in South Africa (88.4% and 81.9%, respectively)
[9], in Costa Rica (88.4% and 89%) [10], in
Zimbabwe (81% and 62%) [11], and in older women
(35—45 years) in China (95% and 85%) [12]. The high
cost and the low specificity of the test are
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to be used as a sole method for primary screening in
women over thirty years, as HPV infection is less
prevalent but more often persistent in older
women [13].
Visual screening techniques have been eval-
uated more intensely in the last decade. The two
visual screening methods, VIA and cervicography
score with an almost identical sensitivity. Cervi-
cography, however, was significantly more spe-
cific. Our study adds to the VIA test characteristics
found in other studies (sensitivity and specificity
for detection of CIN2+ disease was 71.0% and
74.3%, respectively, in China [12], 76.6% and 64.1%
in Zimbabwe [8], 82.6% and 86.5% in India [14],
and 67.4% and 84.9% in South Africa [15]).
Two studies on cervicography provide sensitivity
and specificity for CIN2+ disease of 54.5% and 97.2%
[16], respectively, and 49.3% and 95.0% [6]. A study
from South Africa reports sensitivity and specificity
of 41.8% and 78.8%, respectively, for detection of
any SIL [17]. Our study reports a significantly higher
sensitivity with a comparable specificity compared
to the studies mentioned above.
Colposcopy and colposcopy-directed biopsy to
confirm a positive test result on the primary
screening test is widespread, and is recommended
policy in the industrialized world. This policy is
cumbersome to implement in poor-resource coun-
tries. Colposcopy facilities are costly and require
highly trained medical personnel. The prospect of
having one test that is sensitive enough for screen-
ing, and at the same time specific enough to direct
treatment is appealing. Inevitably, a number of
false-positive cases would be treated unnecessarily,
but a screen- and treat approach using cryotherapy,
which has relatively few side-effects, has shown to
be highly acceptable in poor resource settings [18].
In addition, excision or destruction of the trans-
formation zone are considered preventive for later
development of CIN. HIV-seropositive women, how-
ever, may shed the virus more intensely in the first
weeks after treatment [19], increasing infectious-
ness in case of unprotected sexual intercourse.
During the healing period, the cervix is also more
fragile and more susceptible to HIV infection.
However, it is also possible that, as the cervix heals
after treatment and new epithelium emerges,
often with a shrunken squamo-columnar junction,
the seronegative women may actually get some
long term protective effect from HIV acquisition.
These aspects have to be considered carefully in
regions with high HIV prevalence. Pap smear and
cervicography have the highest specificity and
would therefore cause the least over-treatment.
HPV testing is the least specific and the specificity
of VIA is intermediate but acceptable.
The lack of cervical cancer control programs in
developing countries is largely due to the cost of
those programs, which have to compete for resour-
ces with other health interventions. We did not
assess cost-effectiveness of the different strat-
egies, yet VIA was shown to be a cost-saving
strategy in South Africa, compared to HPV HR
testing and cytology [20].
A limitation of our study is that a number of HPV
tests and cervicographies are missing or non-
interpretable. As this is due to logistics and/or
technical shortages, bias towards the overall
results for those tests is unlikely. On the other
hand, it also demonstrates the difficulties with
using these screening methods in poor resource
settings.
In conclusion, pap smear has the highest specif-
icity, and HPV the highest sensitivity. Cervicography
and VIA are comparable and score in between.
However, from the perspective of the need for a
simple and widely applicable screening test for
cervical (pre-)cancer in poor resource countries,
our study contributes to the growing evidence of
the effectiveness of VIA as a primary screening
tool.
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